Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01119456 · ClinicalTrials.gov registry record · Phase 1
A Study of IMC-RON8 in Advanced Solid Tumors
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT01119456 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 39 participants.
The verdict
NCT01119456, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
A dose escalation study to determine the maximum tolerated dose of IMC-RON8 in participants with solid tumors. Participants can either be dosed once a week, or once every other week.
Interventions
- BIOLOGICAL IMC-RON8
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01119456
The ClinicalTrials.gov registry entry for NCT01119456 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IMC-RON8 is the first listed.
NCT01119456 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01119456 about?
NCT01119456 is a clinical study titled "A Study of IMC-RON8 in Advanced Solid Tumors". A dose escalation study to determine the maximum tolerated dose of IMC-RON8 in participants with solid tumors. Participants can either be dosed once a week, or once every other week.
What is the current status of trial NCT01119456?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2010-05. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01119456?
The interventions under investigation include: IMC-RON8 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01119456?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.